Atrium TherapeuticsRNA -3.49%12 EV-to-EBIT is 0.79 as of Jul. 12, 2026, which is 41% above its 10-year median of 0.56. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 365 Biotechnology companies, Atrium Therapeutics ranks better than 79.18% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Atrium Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-36.46 Mil.
Atrium Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrium Therapeutics EV-to-EBIT Related Terms
Atrium Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atrium Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's EV-to-EBIT falls into.
Atrium Therapeutics's current Enterprise Value is $-51.86 Mil.
Atrium Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrium Therapeutics (RNA) has a EV-to-EBIT of 0.79 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Atrium Therapeutics and its competitors. This is 41% above median its historical median of 0.56. Over the past decade, Atrium Therapeutics' EV-to-EBIT has ranged from 0.21 to 0.87. According to the industry distribution chart, Atrium Therapeutics ranks #76 out of 365 companies in the Biotechnology industry, placing it in the top 20.8%.
Is Atrium Therapeutics' EV-to-EBIT too high?
Atrium Therapeutics' current EV-to-EBIT of 0.79 is 41% above median its 10-year median of 0.56. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 0.87. The Biotechnology industry median EV-to-EBIT is 14.29. Atrium Therapeutics' value of 0.79 is 94.5% below this industry median. Based on the distribution chart, Atrium Therapeutics ranks #76 out of 365 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' EV-to-EBIT compare to CNTN and QTTB?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #76 out of 365 companies for EV-to-EBIT. This places Atrium Therapeutics in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 14.29. Atrium Therapeutics' value of 0.79 is 94.5% below this benchmark. Historically, Atrium Therapeutics' own EV-to-EBIT has ranged from 0.21 to 0.87 over the past decade. While the company's 10-year median is 0.56 vs. the industry median of 14.29, Atrium Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.29, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atrium Therapeutics's current EV-to-EBIT of 0.79 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Atrium Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atrium Therapeutics's current EV-to-EBIT is 0.79, which is 41% above median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current EV-to-EBIT of 0.79. The current EV-to-EBIT is 0.79, which is 41% above median its 10-year median of 0.56 and 94.5% below the Biotechnology industry median of 14.29. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current EV-to-EBIT is 0.79 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 